湖南海利(600731.SH)2019年度淨利潤升96.28%至1.01億元
格隆匯4月6日丨湖南海利(600731.SH)發佈2019年年度報告,公司產品呈現量價齊升新局面, 主要經濟指標實現歷史性跨越,營收首次突破20億元,利潤過億元。
報告期,公司共實現營業收入約21.49億元,同比增長32%;歸屬於母公司淨利潤1.01億元,同比增長96.28%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.14億元,同比增長74.93%;基本每股收益0.2846元,擬公司2019年度利潤不分配,亦不進行資本公積金轉增股本。
公司主營化學農藥(以氨基甲酸酯類農藥、有機磷類農藥、雜環類農藥的原藥及其復配製劑為主;其中以殺蟲劑為主,亦有部分殺菌劑和除草劑)、精細化工產品(以配套農藥原藥生產所需的烷基酚類農藥中間體為主)的研發、生產、銷售。
公司建有年產萬噸規模的氨基甲酸酯類農藥原藥生產裝置、年產萬噸規模的有機磷農藥生產裝置、年產萬噸雜環類農藥生產裝置等,主要生產品種有克百威、仲丁威、異丙威、殘殺威、丁硫克百威、丙硫克百威、滅多威、硫雙威、甲萘威、甲基嘧啶磷、抗蚜威、樂果、甲基硫菌靈、嘧啶醇等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.